Tuberculosis
According to a new report published in the journal PLOS Neglected Tropical Diseases, researchers have identified key barriers to effective rabies control in rural Uganda. The study found that only an estimated 10% of dogs in Uganda are vaccinated against rabies, resulting in about 59,000 human deaths annually. The
Tuberculosis
Researchers from the Tongji University School of Medicine in Shanghai, China, have made a groundbreaking discovery on how Mycobacterium tuberculosis (Mtb), the bacteria responsible for tuberculosis, manipulates host responses to promote its intracellular survival. According to their study, published in Nature Microbiology, Mtb uses a metabolite called linoleic acid to
Tuberculosis
Researchers from the University of Sydney employed whole-slide spatial proteomics to map immune cell organization in tuberculosis-affected human lung tissues. The study's findings suggest that spatial isolation of macrophages from effector lymphocytes may help temper inflammation and prevent lesion progression to necrosis, while also enabling immune evasion by
Tuberculosis
A new study published in the journal PLOS Pathogens has shed light on the critical mechanisms of pulmonary tuberculosis (TB) transmission among humans. The research team, led by Suruchi Lata from Boston University, found that malformed lung repair processes in immunocompetent hosts create a conducive environment for the survival and
Tuberculosis
Investigators at the University of Dublin have made a significant breakthrough in the fight against Mycobacterium tuberculosis (Mtb), a type of bacteria that causes tuberculosis (TB). The research, recently published in the journal Scientific Reports, found that dexamethasone, a glucocorticoid hormone, has the potential to inhibit the growth of Mtb
Tuberculosis
Research at the Swiss Tropical and Public Health Institute has shed light on the significant contribution of Mycobacterium tuberculosis complex (MTBC) lineage 1 (L1) to human tuberculosis (TB) cases, particularly in low- to middle-income countries in South and Southeast Asia, and East Africa. Despite its restricted geographical range, L1 is
Tuberculosis
Multidrug-resistant tuberculosis (MDR-TB) continues to pose a significant clinical challenge, particularly when accompanied by life-threatening complications such as hemoptysis. A recent study reports a rare but serious cause of hemoptysis in TB patients, which is the development of pulmonary artery pseudoaneurysms, known as Rasmussen aneurysms. These aneurysms typically arise within
Tuberculosis
Researchers from PMAS-Arid Agriculture University Rawalpindi have identified a potent phytocompound, o-vanillin, from the plant Datura innoxia that exhibits significant antitubercular activity against the Mycobacterium tuberculosis H37Ra strain. The study, published in Scientific Reports, highlights the compound's potential as a drug against tuberculosis (TB). The researchers employed in
Tuberculosis
Tuberculosis (TB) is a significant global health issue, with the emergence of rifampicin-resistant TB (RR-TB) posing a substantial challenge to control efforts. Research from Zhejiang, China, has shed light on the characteristics of compensatory mutations in RR-TB strains and their association with transmission dynamics in coastal regions of Eastern China.
Tuberculosis
Research published in Clinical Infectious Diseases has shed light on the risk of tuberculosis (TB) in patients treated with biologic therapies (BioT). A study conducted at the University of Barcelona, Spain, assessing the risk of TB in 1368 patients treated with BioT, found that TB infection was diagnosed in 327
Tuberculosis
Current study results on Mycobacterium Infections - Tuberculosis have been published, indicating that scaffold hopping, a medicinal chemistry approach, may accelerate TB drug discovery. Research from Charles University has shown that scaffold hopping can modify the molecular backbone of known bioactive compounds, leading to the discovery of novel drugs with
Tuberculosis
Researchers at the University of Liverpool School Tropical Medicine have presented data on a new treatment regimen for drug-resistant tuberculosis (TB). The study, which took place from January 2020 to December 2023, compared a standard injectable-containing regimen to an all-oral regimen for multidrug- and rifampicin-resistant TB (MDR/RR-TB). The results
